JAMA Network
About The Study: The results of this randomized clinical trial showed that a 15-day course of nirmatrelvir-ritonavir in a population of patients with postacute sequelae of SARS-CoV-2 infection (PASC) was generally safe but did not demonstrate a significant benefit for improving select PASC symptoms in a mostly vaccinated cohort with protracted symptom duration. Further studies are needed to determine the role of antivirals in the treatment of PASC.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
